Shareholder Alert: The Ademi Firm investigates whether KORE Group Holdings Inc. is obtaining a Fair Price for its Public Shareholders [Accessibility Statement] Skip NavigationMILWAUKEE, Feb. 27, 2026 /PRNewswire/ -- Ademi LLP is investigating KORE (NYSE: KORE) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Searchlight Capital Partners and Abry Partners.Click [here] to learn how to join our investigation and obtain additional information or cont ...

Geopolitical risks remain a negative for stocks. Tuesday evening, President Trump said Iranian officials are "again pursuing their sinister nuclear ambitions," boosting speculation that the US may be preparing a military strike on Iran in the coming days. Last Friday, President Trump said that he’s considering a limited military strike on Iran to ramp up pressure on the country to strike a deal over its nuclear program and gave them a March 1-6 deadline for an agreement over the country’s nuclear activities ...

In Tuesday night's State of the Union address, President Trump doubled down on his commitment to tariffs. President Trump’s new 10% global tariffs went into effect on Tuesday after the Supreme Court struck down his global “reciprocal” tariffs last Friday. Mr. Trump subsequently threatened to raise the global tariff rate to 15%, and an administration official said the White House is working on a formal order to implement that higher rate, but the timeline for its implementation has not been finalized. Mr. Tr ...

In Tuesday night's State of the Union address, President Trump doubled down on his commitment to tariffs. President Trump’s new 10% global tariffs went into effect on Tuesday after the Supreme Court struck down his global “reciprocal” tariffs last Friday. Mr. Trump subsequently threatened to raise the global tariff rate to 15%, and an administration official said the White House is working on a formal order to implement that higher rate, but the timeline for its implementation has not been finalized. Mr. Tr ...

Management implemented a fundamental shift in business practices by eliminating historical bulk-purchase discounts for handpieces to prioritize pricing discipline and long-term margin expansion. The commercial organization was realigned into an integrated regional structure to create a single point of accountability for both clinical and sales functions at the local level. A dedicated launch team was formed using top-tier tenured performers to standardize the system activation process and accelerate t ...

We came across a bullish thesis on PROCEPT BioRobotics Corporation on Notes From The Beauty Contest’s Substack by Crashkolnikov. In this article, we will summarize the bulls’ thesis on PRCT. PROCEPT BioRobotics Corporation's share was trading at $29.21 as of February 9th. Is Intuitive Surgical’s (ISRG) Valuation Limiting Further Upside After Earnings? Master Video/Shutterstock.com PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in t ...

​PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is one of the Overlooked Small Cap Stocks to Buy Now. Wall Street is positive on PROCEPT BioRobotics Corporation (NASDAQ:PRCT) ahead of its fiscal Q4 2025 earnings, expected to be released on February 24, 2026. The Street expects the company to post quarterly revenue of around $372.87 million and a GAAP EPS of $1.56. ​Recently, on January 26, Ryan Zimmerman from BTIG maintained a Hold rating on the stock without disclosing any price targets. Earlier on Decemb ...

分组1 - IQVIA Holdings reported quarterly earnings of $3.42 per share, exceeding the Zacks Consensus Estimate of $3.4 per share, and showing an increase from $3.12 per share a year ago, representing an earnings surprise of +0.50% [1] - The company achieved revenues of $4.36 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.83%, and up from $3.96 billion in the same quarter last year [2] - IQVIA has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] 分组2 - The stock has underperformed the market, losing about 10.2% since the beginning of the year, while the S&P 500 has gained 0.5% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $2.95 on revenues of $4.04 billion, and for the current fiscal year, it is $12.93 on revenues of $17.03 billion [7] 分组3 - The Medical - Instruments industry, to which IQVIA belongs, is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable outlook for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for IQVIA was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6]

分组1 - Steris reported quarterly earnings of $2.53 per share, matching the Zacks Consensus Estimate, and showing an increase from $2.32 per share a year ago, with an earnings surprise of -0.10% [1] - The company achieved revenues of $1.5 billion for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 1.08%, and up from $1.37 billion year-over-year [2] - Steris has surpassed consensus EPS estimates three times over the last four quarters, indicating a positive trend in earnings performance [2] 分组2 - The stock has gained approximately 3.2% since the beginning of the year, outperforming the S&P 500's gain of 1.1% [3] - The current consensus EPS estimate for the upcoming quarter is $2.88 on revenues of $1.6 billion, and for the current fiscal year, it is $10.23 on revenues of $5.93 billion [7] - The Medical - Instruments industry, to which Steris belongs, is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable outlook for the sector [8]

Group 1 - The company, PROCEPT BioRobotics Corporation, will report its financial results for Q4 2025 on February 24, 2026, after market close, followed by a conference call at 4:30 p.m. Eastern Time [1] - An in-person investor day event is scheduled for February 25, 2026, at NASDAQ Headquarters in New York City, starting at 8:00 a.m. Eastern Time, with advance registration recommended [2] - Live webcasts of both the financial results and investor day will be available on the company's website, with recordings archived for at least 90 days [3] Group 2 - PROCEPT BioRobotics aims to revolutionize BPH treatment globally by providing advanced robotic solutions that enhance patient outcomes and deliver value [4] - The company manufactures the AQUABEAM® and HYDROS® Robotic Systems, with the HYDROS system being the only AI-powered technology for Aquablation therapy, designed for effective treatment of lower urinary tract symptoms in men [4] - BPH is the most common prostate disease, affecting approximately 40 million men in the United States [4]